by barry101 | Dec 7, 2022 | Press Releases
HOUSTON, Dec. 7, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Nov 10, 2022 | Press Releases
– Continued execution across clinical and preclinical development programs – Three Phase 1b/2 clinical studies with enrollment or dosing now underway – Sufficient capital to fund operations beyond mid-2024 – Company to host conference call and...
by barry101 | Nov 7, 2022 | Press Releases
HOUSTON, Nov. 7, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Oct 14, 2022 | Press Releases
Company enters what it expects to be the final MAD cohort in the first-in-human Phase 1a designed to establish a maximum tolerated dose (MTD) HOUSTON, Oct. 14, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”),...
by barry101 | Sep 27, 2022 | Press Releases
– Preclinical work being conducted is intended to validate in vitro findings in established animal models to determine if further preclinical development and human clinical trials are warranted – Hemorrhagic fever arenaviruses (HFA) represent area of...
by barry101 | Sep 23, 2022 | Press Releases
– Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28 at 11:00 AM ET HOUSTON, Sept. 23, 2022 —...
